 LOS ANGELES--BUSINESS WIRE--- CDXC CellularHealth--ChromaDex Corp. NASDAQ:CDXC announced today the initiation of a human clinical trial of Niagen nicotinamide riboside, or NR investigating its potential to increase milk production among preterm mothers. This new human trial follows promising preclinical results which showed NR supplementation benefited both mother and newborn animals. The double-blinded study will compare mothers levels of milk production and other markers of metabolism between the experiment 